Date of Award
Selective Evidence-Based Medicine Review
Master of Science in Health Sciences - Physician Assistant
Physician Assistant Studies
John Cavenagh, MBA, PhD, PA-C
Objective: The purpose of this careful EBM review is to determine whether lisdexamfetamine dimesylate (LDX) is safe and effective in reducing attention-deficit/hyperactivity disorder (ADHD) symptoms.
Study Design: A systematic review of two randomized controlled studies and one double-blind, 2-arm, parallel-group placebo-controlled RWP published between 2011-2014, all in the English language.
Data Sources: Two randomized controlled trials and one double-blind, 2-arm, parallel-group placebo-controlled RWP published between 2011 and 2014 which were found using PubMed and Cochrane databases.
Outcomes Measured: ADHD global symptomatic improvement was measured using Clinical Global Impressions – Severity of Illness (CGI-S), Clinical Global Impression-Improvement (CGI-I) and ADHD Rating Scale-IV (ADHD-RS-IV). Safety was measured using treatment-emergent adverse events (TEAEs).
Results: Two randomized controlled trials and one double-blind, 2-arm, parallel-group placebo-controlled RWP revealed that using LDX helped reduce ADHD symptoms greater than the placebo it was compared against. The most common side effects caused by LDX were a headache, insomnia, and decreased appetite.
Conclusion: The literature utilized in this EBM project revealed that children and adolescents that used Vyvanse, demonstrated improvement in attention-deficit/hyperactivity disorder (ADHD) symptomatology. Additionally, it was found that LDX was safe for use as the side effects were benign.
Drelich, Jordan A., "Is Lisdexamfetamine Dimesylate Safe and Effective in Reducing ADHD Symptoms?" (2017). PCOM Physician Assistant Studies Student Scholarship. 397.